InQpharm Europe Ltd., Invision House, Wilbury Way, Hitchin, Hertfordshire SG4 0TY, UK.
Analyze & Realize GmbH, Waldseeweg 6, 13467 Berlin, Germany.
Evid Based Complement Alternat Med. 2014;2014:943713. doi: 10.1155/2014/943713. Epub 2014 Aug 28.
Sedentary lifestyle and caloric overconsumption are the key determinants of the escalating obesity prevalence. Reducing dietary fat absorption may help to induce a negative energy balance and thus help in managing weight problem. Apart from approved drug therapies, weight problems may also be aided with alternative and natural treatments. This paper compiled and reviewed the efficacy and safety of Litramine IQP-G-002AS, an Opuntia ficus-indica (OFI) derived fiber, in reducing dietary fat absorption and promoting weight loss. Evidence reviewed shows that Litramine IQP-G-002AS displays efficacy in promoting fat excretion and weight loss in four randomized, placebo-controlled clinical studies (including an unpublished pilot study). With a daily dosage of 3 g over a seven-day period, Litramine IQP-G-002AS showed an increased faecal fat excretion compared with placebo (15.8% (SD 5.8%) versus 4.6% (SD 3.1%); P < 0.001). In a 12-week study, significant greater weight loss (3.8 kg (SD 1.8 kg) versus 1.4 kg (SD 2.6 kg); P < 0.001) was observed in overweight and obese subjects treated with Litramine IQP-G-002AS as compared to placebo. No relevant gastrointestinal side effects have been reported for Litramine IQP-G-002AS at the dosages studied.
sedentary lifestyle and caloric overconsumption are the key determinants of the escalating obesity prevalence. Reducing dietary fat absorption may help to induce a negative energy balance and thus help in managing weight problem. Apart from approved drug therapies, weight problems may also be aided with alternative and natural treatments. This paper compiled and reviewed the efficacy and safety of Litramine IQP-G-002AS, an Opuntia ficus-indica (OFI) derived fiber, in reducing dietary fat absorption and promoting weight loss. Evidence reviewed shows that Litramine IQP-G-002AS displays efficacy in promoting fat excretion and weight loss in four randomized, placebo-controlled clinical studies (including an unpublished pilot study). With a daily dosage of 3 g over a seven-day period, Litramine IQP-G-002AS showed an increased faecal fat excretion compared with placebo (15.8% (SD 5.8%) versus 4.6% (SD 3.1%); P < 0.001). In a 12-week study, significant greater weight loss (3.8 kg (SD 1.8 kg) versus 1.4 kg (SD 2.6 kg); P < 0.001) was observed in overweight and obese subjects treated with Litramine IQP-G-002AS as compared to placebo. No relevant gastrointestinal side effects have been reported for Litramine IQP-G-002AS at the dosages studied.
久坐的生活方式和热量摄入过多是肥胖患病率不断上升的关键决定因素。减少膳食脂肪吸收可能有助于诱导负能平衡,从而有助于控制体重问题。除了经过批准的药物治疗外,体重问题也可以通过替代和自然疗法来辅助治疗。本文汇编和综述了Litramine IQP-G-002AS(一种源自仙人掌的纤维)在减少膳食脂肪吸收和促进体重减轻方面的功效和安全性。综述的证据表明,Litramine IQP-G-002AS 在四项随机、安慰剂对照的临床研究(包括一项未发表的初步研究)中显示出促进脂肪排泄和体重减轻的功效。在为期七天的时间内,每天服用 3 克 Litramine IQP-G-002AS 与安慰剂相比,粪便脂肪排泄量增加(15.8%(SD 5.8%)与 4.6%(SD 3.1%);P<0.001)。在一项为期 12 周的研究中,与安慰剂相比,超重和肥胖受试者接受 Litramine IQP-G-002AS 治疗后体重显著减轻(3.8kg(SD 1.8kg)与 1.4kg(SD 2.6kg);P<0.001)。在研究的剂量下,Litramine IQP-G-002AS 没有报告相关的胃肠道副作用。